Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Existing therapies for epilepsy are primarily symptomatic and target mechanisms of neuronal transmission in order to restore the excitatory-inhibitory imbalance in the brain after seizures.However, approximately one third of individuals with epilepsy have medically refractory epilepsy and do not respond to available treatments. There is a critical need for the development of therapeutics that extend beyond manipulation of excitatory neurotransmission and target pathological changes underlying the cause of the disease. Epilepsy is a multifaceted condition, and it could be that effective treatment involves the targeting of several mechanisms. There is evidence for both dysregulated PI3K/Akt/mTOR (mTOR) signaling and heightened neuroinflammatory processes following seizures in the brain. Signaling via mTOR has been implicated in several epileptogenic processes, including synaptic plasticity mechanisms and changes in ion channel expression following seizures. Inflammatory signaling, such as increased synthesis of cytokines and other immune molecules, has also shown to play a significant role in the development of chronic epilepsy. mTOR pathway activation and immune signaling are known to interact in normal physiological states, as well as influence one another following seizures. Simultaneous inhibition of both processes could be a promising therapeutic avenue to prevent the development of chronic epilepsy by targeting two key pathological mechanisms implicated in epileptogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Synaptic Pruning by Microglia Is Necessary for Normal Brain Development
Paolicelli, R. C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., Ferreira, T. A., Guiducci, E., Dumas, L., et al. (2011) · Science · doi:10.1126/science.1202529 · Cited by 4,244
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Understanding the mechanism of IL-1β secretion
Lopez-Castejon, G., & Brough, D. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.10.001 · Cited by 1,519
Differential Regulation of AMPA Receptor and GABA Receptor Trafficking by Tumor Necrosis Factor-α
Stellwagen, D., Beattie, E. C., Seo, J. Y., & Malenka, R. C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4486-04.2005 · Cited by 985
Viviani, B., Bartesaghi, S., Gardoni, F., Vezzani, A., Behrens, M. M., Bartfai, T., Binaglia, M., Corsini, E., Di Luca, M., Galli, C. L., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08692.2003 · Cited by 893
Deverman, B. E., & Patterson, P. H. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.002 · Cited by 865
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Comorbidities of epilepsy: current concepts and future perspectives
Keezer, M. R., Sisodiya, S. M., & Sander, J. W. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00225-2 · Cited by 778
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Berkowitz, N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31419-2 · Cited by 764
Takeuchi, H., Jin, S., Wang, J., Zhang, G., Kawanokuchi, J., Kuno, R., Sonobe, Y., Mizuno, T., & Suzumura, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600504200 · Cited by 749
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.
Zeng, L., Xu, L., Gutmann, D. H., & Wong, M. (2008) · Annals of Neurology · doi:10.1002/ana.21331 · Cited by 639
Anticonvulsant Mechanisms of the Ketogenic Diet
Bough, K. J., & Rho, J. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00915.x · Cited by 523
Westman, E. C., Yancy, W. S., Mavropoulos, J. C., Marquart, M., & McDuffie, J. R. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-36 · Cited by 475
Zhou, J., Blundell, J., Ogawa, S., Kwon, C.-H., Zhang, W., Sinton, C., Powell, C. M., & Parada, L. F. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5685-08.2009 · Cited by 441
mTOR complexes in neurodevelopmental and neuropsychiatric disorders
Costa-Mattioli, M., & Monteggia, L. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3546 · Cited by 367
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
The role of mammalian target of rapamycin (mTOR) in insulin signaling
Yoon, M.-S. (2017) · Nutrients · doi:10.3390/nu9111176 · Cited by 300
Epilepsy in fragile X syndrome
Berry‐Kravis, E. (2002) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2002.tb00277.x · Cited by 271
Jhanwar-Uniyal, M., Wainwright, J. V., Mohan, A. L., Tobias, M. E., Murali, R., Gandhi, C. D., & Schmidt, M. H. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.003 · Cited by 268
The IL-1β system in epilepsy-associated malformations of cortical development
Ravizza, T., Boer, K., Redeker, S., Spliet, W. G. M., van Rijen, P. C., Troost, D., Vezzani, A., & Aronica, E. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.003 · Cited by 268
Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites
Raab-Graham, K. F., Haddick, P. C. G., Jan, Y. N., & Jan, L. Y. (2006) · Science · doi:10.1126/science.1131693 · Cited by 267
Michinaga, S., & Koyama, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030571 · Cited by 263
Cytokine Signaling Modulates Blood-Brain Barrier Function
Pan, W., P. Stone, K., Hsuchou, H., K. Manda, V., Zhang, Y., & J. Kastin, A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798220918 · Cited by 241
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells
Schmitz, F., Heit, A., Dreher, S., Eisenächer, K., Mages, J., Haas, T., Krug, A., Janssen, K., Kirschning, C. J., & Wagner, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838761 · Cited by 212
Marchi, N., Granata, T., Freri, E., Ciusani, E., Ragona, F., Puvenna, V., Teng, Q., Alexopolous, A., & Janigro, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018200 · Cited by 150
Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage
Brewster, A. L., Lugo, J. N., Patil, V. V., Lee, W. L., Qian, Y., Vanegas, F., & Anderson, A. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057808 · Cited by 112
Self-citationSha, L.-Z., Xing, X.-L., Zhang, D., Yao, Y., Dou, W.-C., Jin, L.-R., Wu, L.-W., & Xu, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039152 · Cited by 70
Lee, H.-K., Kwon, B., Lemere, C. A., de la Monte, S., Itamura, K., Ha, A. Y., & Querfurth, H. W. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161029 · Cited by 57
Cited by
Neuroinflammation and Proinflammatory Cytokines in Epileptogenesis
Soltani Khaboushan, A., Yazdanpanah, N., & Rezaei, N. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02725-6 · Cited by 262
mTOR and neuroinflammation in epilepsy: implications for disease progression and treatment
Ravizza, T., Scheper, M., Di Sapia, R., Gorter, J., Aronica, E., & Vezzani, A. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-024-00805-1 · Cited by 141
“…by various factors, including amino acids, glucose, fatty acids, cytokines (for example, IL-1β, tumour necrosis factor (TNF), IL-6 and HMGB1) 20,21 , growth factors (for example, brain-derived neurotrophic factor, insulin-like growth factor 1, vascular endothelial growth factor), hormones…”
InfluentialShao, E., Chang, C.-W., Li, Z., Yu, X., Ho, K., Zhang, M., Wang, X., Simms, J., Lo, I., Speckart, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm5527 · Cited by 54
“We previously showed that genetically reducing overall expression of the microtubule-associated protein TAU can prevent or diminish multiple disease manifestations in mouse models of such ASDs, including DS mice (24, 25).”
BackgroundInfluentialBeretta, S., Gritti, L., Ponzoni, L., Scalmani, P., Mantegazza, M., Sala, M., Verpelli, C., & Sala, C. (2022) · Molecular Autism · doi:10.1186/s13229-021-00484-0 · Cited by 18
Metadata
- Authors
- Hodges, S. L., & Lugo, J. N.
- Venue
- Epilepsy Research
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 161
- Pages
- 106282
- ISSN
- 0920-1211 (ISSN-L)
- OpenAlex
- W3003340868
- Cited by
- 84
- References
- 31
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.